Mosaic ImmunoEngineering Inc. (CPMV)
USD 0.65
(-22.25%)
USD 0.65
(-22.25%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 2.62 Million USD | -24.95% |
| 2021 | 3.5 Million USD | 0.0% |
| 2019 | 734.06 Thousand USD | 0.0% |
| 2017 | 1.04 Million USD | -13.91% |
| 2016 | 1.21 Million USD | -22.84% |
| 2015 | 1.57 Million USD | 9.64% |
| 2014 | 1.43 Million USD | -13.39% |
| 2013 | 1.66 Million USD | 20.17% |
| 2012 | 1.38 Million USD | -30.75% |
| 2011 | 1.99 Million USD | -55.34% |
| 2010 | 4.46 Million USD | -44.41% |
| 2009 | 8.03 Million USD | -13.69% |
| 2008 | 9.3 Million USD | 19.32% |
| 2007 | 7.8 Million USD | -48.28% |
| 2006 | 15.08 Million USD | 139.62% |
| 2005 | 6.29 Million USD | 117.42% |
| 2004 | 2.89 Million USD | 60.55% |
| 2003 | 1.8 Million USD | -29.15% |
| 2002 | 2.54 Million USD | -37.63% |
| 2001 | 4.08 Million USD | -15.1% |
| 2000 | 4.8 Million USD | 45.69% |
| 1999 | 3.29 Million USD | -20.77% |
| 1998 | 4.16 Million USD | 2.1% |
| 1997 | 4.07 Million USD | 10.12% |
| 1996 | 3.7 Million USD | 53.78% |
| 1995 | 2.4 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q3 | 311.87 Thousand USD | -11.53% |
| 2023 Q1 | 459.77 Thousand USD | -7.59% |
| 2023 Q2 | 352.5 Thousand USD | -23.33% |
| 2022 Q4 | 497.55 Thousand USD | -3.8% |
| 2022 Q2 | 883.72 Thousand USD | 21.22% |
| 2022 Q3 | 517.2 Thousand USD | -41.47% |
| 2022 Q1 | 729.03 Thousand USD | -11.63% |
| 2022 FY | 2.62 Million USD | -24.95% |
| 2021 FY | 3.5 Million USD | 0.0% |
| 2021 Q1 | 804.44 Thousand USD | 28.0% |
| 2021 Q2 | 910.7 Thousand USD | 13.21% |
| 2021 Q3 | 961.05 Thousand USD | 5.53% |
| 2021 Q4 | 824.95 Thousand USD | -14.16% |
| 2020 Q4 | 628.46 Thousand USD | 462.09% |
| 2020 Q2 | 101.7 Thousand USD | -2.05% |
| 2020 Q1 | 103.83 Thousand USD | -78.7% |
| 2020 Q3 | 111.8 Thousand USD | 9.93% |
| 2019 Q4 | 487.44 Thousand USD | 60.85% |
| 2019 FY | 734.06 Thousand USD | 0.0% |
| 2019 Q1 | 158.62 Thousand USD | 10.21% |
| 2019 Q2 | 228.03 Thousand USD | 43.76% |
| 2019 Q3 | 303.03 Thousand USD | 32.89% |
| 2018 Q3 | 203.48 Thousand USD | -13.65% |
| 2018 Q1 | 274 Thousand USD | 7.81% |
| 2018 Q2 | 235.64 Thousand USD | -14.0% |
| 2018 Q4 | 143.92 Thousand USD | -29.27% |
| 2017 Q2 | 328.46 Thousand USD | 16.78% |
| 2017 FY | 1.04 Million USD | -13.91% |
| 2017 Q1 | 281.26 Thousand USD | -1.05% |
| 2017 Q3 | 283.32 Thousand USD | -13.74% |
| 2017 Q4 | 254.15 Thousand USD | -10.29% |
| 2016 Q4 | 284.24 Thousand USD | -11.83% |
| 2016 Q3 | 322.37 Thousand USD | -25.18% |
| 2016 Q1 | 405.24 Thousand USD | 18.42% |
| 2016 Q2 | 430.86 Thousand USD | 6.32% |
| 2016 FY | 1.21 Million USD | -22.84% |
| 2015 FY | 1.57 Million USD | 9.64% |
| 2015 Q4 | 342.19 Thousand USD | -14.06% |
| 2015 Q3 | 398.16 Thousand USD | -13.47% |
| 2015 Q2 | 460.13 Thousand USD | 85.79% |
| 2015 Q1 | 247.66 Thousand USD | -30.7% |
| 2014 FY | 1.43 Million USD | -13.39% |
| 2014 Q1 | 379 Thousand USD | 1.48% |
| 2014 Q2 | 468.94 Thousand USD | 23.73% |
| 2014 Q3 | 372.62 Thousand USD | -20.54% |
| 2014 Q4 | 357.37 Thousand USD | -4.09% |
| 2013 FY | 1.66 Million USD | 20.17% |
| 2013 Q4 | 373.49 Thousand USD | -14.86% |
| 2013 Q3 | 438.65 Thousand USD | 8.02% |
| 2013 Q2 | 406.08 Thousand USD | 17.67% |
| 2013 Q1 | 345.11 Thousand USD | 44.9% |
| 2012 FY | 1.38 Million USD | -30.75% |
| 2012 Q1 | 623.37 Thousand USD | -23.66% |
| 2012 Q4 | 238.17 Thousand USD | -39.25% |
| 2012 Q2 | 447.94 Thousand USD | -28.14% |
| 2012 Q3 | 392.06 Thousand USD | -12.48% |
| 2011 Q3 | 906.7 Thousand USD | 14.34% |
| 2011 Q2 | 793 Thousand USD | -19.82% |
| 2011 Q1 | 989.05 Thousand USD | -9.92% |
| 2011 FY | 1.99 Million USD | -55.34% |
| 2011 Q4 | 816.57 Thousand USD | -9.94% |
| 2010 Q1 | 1.61 Million USD | -36.66% |
| 2010 Q2 | 1.62 Million USD | 0.55% |
| 2010 FY | 4.46 Million USD | -44.41% |
| 2010 Q3 | 1.58 Million USD | -2.39% |
| 2010 Q4 | 1.09 Million USD | -30.78% |
| 2009 Q2 | 2.84 Million USD | 28.95% |
| 2009 Q3 | 2.24 Million USD | -21.18% |
| 2009 Q4 | 2.55 Million USD | 13.81% |
| 2009 FY | 8.03 Million USD | -13.69% |
| 2009 Q1 | 2.2 Million USD | -5.23% |
| 2008 Q1 | 1.78 Million USD | -24.98% |
| 2008 Q3 | 1.93 Million USD | 16.58% |
| 2008 FY | 9.3 Million USD | 19.32% |
| 2008 Q2 | 1.65 Million USD | -7.05% |
| 2008 Q4 | 2.32 Million USD | 20.55% |
| 2007 Q1 | 1.75 Million USD | -78.22% |
| 2007 FY | 7.8 Million USD | -48.28% |
| 2007 Q3 | 1.98 Million USD | -22.46% |
| 2007 Q2 | 2.56 Million USD | 46.5% |
| 2007 Q4 | 2.37 Million USD | 19.46% |
| 2006 Q1 | 2.12 Million USD | 22.37% |
| 2006 Q3 | 2.73 Million USD | 185.96% |
| 2006 Q2 | -3.17 Million USD | -249.89% |
| 2006 FY | 15.08 Million USD | 139.62% |
| 2006 Q4 | 8.03 Million USD | 194.1% |
| 2005 FY | 6.29 Million USD | 117.42% |
| 2005 Q2 | 800.34 Thousand USD | -29.77% |
| 2005 Q3 | 5.61 Million USD | 602.15% |
| 2005 Q1 | 1.13 Million USD | 155.16% |
| 2005 Q4 | 1.73 Million USD | -69.16% |
| 2004 Q2 | 449.1 Thousand USD | 6.91% |
| 2004 Q3 | 508.7 Thousand USD | 13.27% |
| 2004 FY | 2.89 Million USD | 60.55% |
| 2004 Q1 | 420.09 Thousand USD | -3.1% |
| 2004 Q4 | 446.58 Thousand USD | -12.21% |
| 2003 Q3 | 500.59 Thousand USD | -10.26% |
| 2003 Q2 | 557.84 Thousand USD | 1.5% |
| 2003 Q1 | 549.6 Thousand USD | -25.86% |
| 2003 FY | 1.8 Million USD | -29.15% |
| 2003 Q4 | 433.52 Thousand USD | -13.4% |
| 2002 Q1 | 967.12 Thousand USD | -13.19% |
| 2002 FY | 2.54 Million USD | -37.63% |
| 2002 Q4 | 741.35 Thousand USD | 6.46% |
| 2002 Q3 | 696.38 Thousand USD | -18.09% |
| 2002 Q2 | 850.21 Thousand USD | -12.09% |
| 2001 FY | 4.08 Million USD | -15.1% |
| 2001 Q1 | 1.32 Million USD | 15.45% |
| 2001 Q4 | 1.11 Million USD | -3.08% |
| 2001 Q3 | 1.14 Million USD | -20.81% |
| 2001 Q2 | 1.45 Million USD | 9.68% |
| 2000 FY | 4.8 Million USD | 45.69% |
| 2000 Q4 | 1.14 Million USD | 29.49% |
| 2000 Q3 | 885.3 Thousand USD | 14.7% |
| 2000 Q1 | 904.35 Thousand USD | 19.93% |
| 2000 Q2 | 771.83 Thousand USD | -14.65% |
| 1999 Q4 | 754.04 Thousand USD | -13.25% |
| 1999 Q3 | 869.19 Thousand USD | 0.0% |
| 1999 FY | 3.29 Million USD | -20.77% |
| 1998 FY | 4.16 Million USD | 2.1% |
| 1997 FY | 4.07 Million USD | 10.12% |
| 1996 FY | 3.7 Million USD | 53.78% |
| 1995 FY | 2.4 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -96.755% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 47.888% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 91.109% |
| Nascent Biotech, Inc. | 2.22 Million USD | -17.832% |
| Rebus Holdings, Inc. | 664 Thousand USD | -295.711% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 92.947% |
| Qrons Inc. | 643.67 Thousand USD | -308.205% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -574.474% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 95.426% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -532.408% |
| Skye Bioscience, Inc. | 13.54 Million USD | 80.605% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 96.972% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 46.572% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -903.921% |
| SQZ Biotechnologies Company | 85.61 Million USD | 96.931% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 9.9% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -74.947% |
| Mesoblast Limited | 5.9 Million USD | 55.481% |
| Marizyme, Inc. | 19.23 Million USD | 86.343% |
| Genus plc | 147.7 Million USD | 98.221% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 70.071% |
| Pharming Group N.V. | 225.49 Million USD | 98.835% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -28.253% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -95.858% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 68.491% |
| ContraFect Corporation | 56.88 Million USD | 95.381% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 40.401% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -77.685% |
| IMV Inc. | 37.7 Million USD | 93.032% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 5.836% |
| MultiCell Technologies, Inc. | 567.42 USD | -462964.749% |
| ONE Bio Corp. | 6.44 Million USD | 59.225% |
| Accustem Sciences Inc. | 3.74 Million USD | 29.866% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 96.943% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -393.93% |
| Q BioMed Inc. | 3.43 Million USD | 23.544% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 89.369% |
| Biomind Labs Inc. | 994.18 Thousand USD | -164.29% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 97.355% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -49.318% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 60.888% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -40.934% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 10610.088% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 83.588% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -43.182% |
| GB Sciences, Inc. | 1.42 Million USD | -84.97% |
| Alpha Cognition Inc. | 9.7 Million USD | 72.928% |
| HST Global, Inc. | 140.9 Thousand USD | -1764.721% |
| CSL Limited | 3.44 Billion USD | 99.924% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -133.576% |
| Halberd Corporation | 74.84 Thousand USD | -3410.759% |
| Enzolytics Inc. | 2.17 Million USD | -20.556% |
| Agentix Corp. | 1.37 Million USD | -91.544% |
| Resverlogix Corp. | 12.71 Million USD | 79.33% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 28.027% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.829% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -151.678% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -9.255% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -66.367% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 22.833% |
| AVAX Technologies, Inc. | 7.31 Million USD | 64.057% |
| Zenith Capital Corp. | 8.94 Million USD | 70.619% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.682% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -14982.498% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -7.014% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -1432.002% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -36.786% |
| Kadimastem Ltd | 2.41 Million USD | -9.021% |
| Helix BioMedix, Inc. | 1.97 Million USD | -33.239% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 75.821% |
| BioStem Technologies, Inc. | 22.97 Million USD | 88.563% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -1347.79% |
| LadRx Corporation | 3.81 Million USD | 31.069% |
| Cell Source, Inc. | 4.32 Million USD | 39.253% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -184.515% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -184.515% |
| NovAccess Global Inc. | 2.46 Million USD | -6.517% |
| Affymax, Inc. | 39.38 Million USD | 93.329% |
| Itoco Inc. | 919.14 Thousand USD | -185.867% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 38.007% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -134.81% |
| Mobile Lads Corp. | 554.54 Thousand USD | -373.815% |
| CytoDyn Inc. | 18.05 Million USD | 85.45% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -10339.517% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -1093.905% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -85.064% |
| SYBLEU INC | 160.87 Thousand USD | -1533.259% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -44.662% |
| International Stem Cell Corporation | 5.27 Million USD | 50.151% |
| Bioxytran, Inc. | 3.82 Million USD | 31.219% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -4891.304% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -12816.099% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 92.755% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -62.393% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -257.08% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 15.541% |
| Neutra Corp. | 243.82 Thousand USD | -977.644% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 84.949% |
| PureTech Health plc | 144.59 Million USD | 98.183% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 87.176% |
| IXICO plc | 4.7 Million USD | 44.178% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 70.132% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 97.769% |
| CSL Limited | 3.89 Billion USD | 99.933% |
| Cellectis S.A. | 97.32 Million USD | 97.3% |